AstraZeneca (NASDAQ: AZN) has reassured investors that potential U.S. pharmaceutical import tariffs will have a limited impact on its financial outlook, even as the company missed first-quarter revenue estimates and
All posts tagged in AstraZeneca 2025 earnings guidance
1Article
Categories
